Cargando…

Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients.

Serum testosterone, 17 beta-oestradiol, luteinising hormone (LH) and prolactin were measured in 28 postmenopausal breast cancer patients after mastectomy and in 30 postmenopausal normal controls. In the patient group, mean levels of oestradiol, LH and prolactin did not differ significantly from thos...

Descripción completa

Detalles Bibliográficos
Autores principales: Secreto, G., Recchione, C., Cavalleri, A., Miraglia, M., Dati, V.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1983
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011282/
https://www.ncbi.nlm.nih.gov/pubmed/6824571
_version_ 1782136499056148480
author Secreto, G.
Recchione, C.
Cavalleri, A.
Miraglia, M.
Dati, V.
author_facet Secreto, G.
Recchione, C.
Cavalleri, A.
Miraglia, M.
Dati, V.
author_sort Secreto, G.
collection PubMed
description Serum testosterone, 17 beta-oestradiol, luteinising hormone (LH) and prolactin were measured in 28 postmenopausal breast cancer patients after mastectomy and in 30 postmenopausal normal controls. In the patient group, mean levels of oestradiol, LH and prolactin did not differ significantly from those of the control group. Mean testosterone levels were higher in breast cancer patients than in normal controls, either considering the overall groups (P less than 0.001) or dividing them into subgroups according to years since menopause. Breast cancer patients were divided into 2 subgroups according to time since mastectomy: 19 patients had been examined within a year of mastectomy and 9 patients some years after mastectomy. Testosterone, but not oestradiol, LH or prolactin values in each subgroup were still significantly higher (P less than 0.001 and P less than 0.02, respectively) than in normal controls. Years since menopause were significantly correlated with testosterone (r = 0.533, P less than 0.01) but not with the other hormones in the cancer group. These results confirm our previous findings of increased urinary testosterone values in postmenopausal breast cancer patients and support the hypothesis that androgens may play a role in the development of breast cancer.
format Text
id pubmed-2011282
institution National Center for Biotechnology Information
language English
publishDate 1983
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20112822009-09-10 Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients. Secreto, G. Recchione, C. Cavalleri, A. Miraglia, M. Dati, V. Br J Cancer Research Article Serum testosterone, 17 beta-oestradiol, luteinising hormone (LH) and prolactin were measured in 28 postmenopausal breast cancer patients after mastectomy and in 30 postmenopausal normal controls. In the patient group, mean levels of oestradiol, LH and prolactin did not differ significantly from those of the control group. Mean testosterone levels were higher in breast cancer patients than in normal controls, either considering the overall groups (P less than 0.001) or dividing them into subgroups according to years since menopause. Breast cancer patients were divided into 2 subgroups according to time since mastectomy: 19 patients had been examined within a year of mastectomy and 9 patients some years after mastectomy. Testosterone, but not oestradiol, LH or prolactin values in each subgroup were still significantly higher (P less than 0.001 and P less than 0.02, respectively) than in normal controls. Years since menopause were significantly correlated with testosterone (r = 0.533, P less than 0.01) but not with the other hormones in the cancer group. These results confirm our previous findings of increased urinary testosterone values in postmenopausal breast cancer patients and support the hypothesis that androgens may play a role in the development of breast cancer. Nature Publishing Group 1983-02 /pmc/articles/PMC2011282/ /pubmed/6824571 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Secreto, G.
Recchione, C.
Cavalleri, A.
Miraglia, M.
Dati, V.
Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients.
title Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients.
title_full Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients.
title_fullStr Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients.
title_full_unstemmed Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients.
title_short Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients.
title_sort circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011282/
https://www.ncbi.nlm.nih.gov/pubmed/6824571
work_keys_str_mv AT secretog circulatinglevelsoftestosterone17betaoestradiolluteinisinghormoneandprolactininpostmenopausalbreastcancerpatients
AT recchionec circulatinglevelsoftestosterone17betaoestradiolluteinisinghormoneandprolactininpostmenopausalbreastcancerpatients
AT cavalleria circulatinglevelsoftestosterone17betaoestradiolluteinisinghormoneandprolactininpostmenopausalbreastcancerpatients
AT miragliam circulatinglevelsoftestosterone17betaoestradiolluteinisinghormoneandprolactininpostmenopausalbreastcancerpatients
AT dativ circulatinglevelsoftestosterone17betaoestradiolluteinisinghormoneandprolactininpostmenopausalbreastcancerpatients